CD44 mAb engineered surface modified Poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles loaded with Aprepitant and Etoricoxib for simultaneous targeting of TNBC stem cells and cancer cells.
Implementing Organization
JSS College of Pharmacy, Ooty
Principal Investigator
Dr. Praveen Thaggikuppe Krishnamurthy
JSS College of Pharmacy, Ooty
CO-Principal Investigator
Dr. Vaishali Manikrao Patil
Krishna Path Incubation Society TBI- KIET Group Of Institutions, Ghaziabad, Uttar Pradesh
Kiet Group of Institutions
CO-Principal Investigator
Dr. Chandrashekhar Venkaraddi Mangannavar
Institute of Public Health
Project Overview
TNBC, an aggressive subtype of breast cancer, lacks estrogen and progesterone receptors and the human epidermal growth factor receptor gene. Current therapeutic options focus on targeting TNBC cells, but conventional chemotherapeutic medications can spare TNBC stem cells, increasing the risk of tumor relapse. A successful strategy should target both TNBC cells and TNBCsCs simultaneously. The role of sP or tNK-1R and COX-2 enzyme in TNBC progression is well-established. The study hypothesizes that combining Aprepitant and Etoricoxib could introduce a new strategy in chemotherapy with superior anti-TNBC potential. Polymeric nanoparticles (PNPs) have been investigated as nano drug delivery systems due to their biodegradability, biocompatibility, and non-toxic properties. Engineering PNPs with TNBC-specific markers like CD44 can enhance the therapeutic efficacy of loaded drugs while minimizing toxic effects.
JSS College of Pharmacy, Ooty
Kiet Group of Institutions
Acces sibility Controls